טוען...
Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study
BACKGROUND: The combination of umeclidinium (UMEC), a long-acting muscarinic receptor antagonist, and vilanterol (VI), a selective long-acting β(2) agonist, is in development for the treatment of chronic obstructive pulmonary disease (COPD). This study evaluated the pharmacokinetics, safety and tole...
שמור ב:
| Main Authors: | , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove Medical Press
2013
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3615930/ https://ncbi.nlm.nih.gov/pubmed/23569370 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S40859 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|